Loading…
BOLT
Bolt Biotherapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 097702203
$3.71+3.34%Price as of Sep 22, 22:38 UTC · updated once a day, after the close
Key metrics
- Market cap
- $7.15M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$16.51
- ROE
- -111.65%
- Profit margin
- 0.00%
- Revenue growth
- -99.70%
- Beta
- 1.09
- 52-week high
- $7.20
- 52-week low
- $3.10
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.6% over 5Y.
today you would have $14.15▼ -98.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $5.47 | $10.70 | $22.40 | $26.00 | $98.00 | |
| P/S | 5.4x | 1.4x | 2.7x | 5.4x | 8.6x | 145.7x |
| P/B | 0.4x | 0.4x | 0.4x | 0.4x | 0.3x | 0.7x |
| EPS | -$17.85 | -$33.06 | -$36.60 | -$47.20 | -$59.40 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INBSIntelligent Bio Solutions Inc | $2.36 | — | 1.2x | — | -307.69% | $7.14M |
| CURXCuranex Pharmaceuticals Inc | $4.56 | — | 1.4x | — | -411.08% | $7.15M |
| CANFCan-Fite BioPharma Ltd. | $3.40 | — | 0.8x | — | -178.24% | $7.28M |
| INMInMed Pharmaceuticals Inc. | $1.38 |
About the company
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
- 23
- Redwood City, United States
Company description provided by Yahoo Finance.